Anti-IDH2 Polyclonal Antibody Knockout Validated

In this issue of Blood, Stein et al(1) report the outcomes for all isocitrate dehydrogenase-2 (IDH2) mutant relapsed or refractory acute myeloid leukemia (R/R AML) patients treated with enasidenib in the first phase 1/2 study including data on molecular clearance and molecular relationships to response or resistance.

While the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) has been a remarkably successful example for differentiation therapy of cancer, the recently developed therapeutics of mutant IDH2 (mIDH2)-associated leukemia by specific mIDH2 inhibitors is launching another promising campaign. Interestingly, a recent study in Cell Research by Mugoni et al. demonstrated a sensitivity of the mIDH2 leukemia to the APL-like ATRA/ATO combination therapy, narrating a convergence of two tales.